Jefferson Digital Commons quarterly report: July-September 2018 [PDF]
, 2018 This quarterly report includes: New Collection Alert Articles Code Red: Battling the Plague of Gun Violence Dissertations From the Archives Grand Rounds and Lectures House Staff Quality Improvement and Patient Safety Posters Journals and Newsletters ...
Copeland, LIBT, James +1 more
core +1 more source
Российский кардиологический журнал, 2019 Reducing of cardiovascular risk, morbidity and mortality is considered as one of the main aims of modern cardiology, which should help increase life expectancy.
Yu. A. Karpov
doaj +1 more source
Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model [PDF]
, 2015 Markus Honickel +4 more
openalex +1 more source
Viewpoint Stroke prevention in recent guidelines for the management of patients with atrial fibrillation: An appraisal. [PDF]
, 2017 Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions.
Camm, AJ +4 more
core +3 more sources
Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
Vascular Health and Risk Management, 2019 David Giannandrea,1,2,* Anna Mengoni,3,* Erberto Carluccio,3 Giuseppe Ambrosio31Neurology Departement - Stroke Unit, Gubbio/Gualdo Tadino Hospitals, Perugia, Italy; 2Association “Naso Sano”, Umbria Regional Registry of No-Profit Organization,
Giannandrea D +3 more
doaj
Case Reports in Cardiology, 2017 Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation.
Steven Song +5 more
doaj +1 more source
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study [PDF]
, 2016 Stephan Glund +11 more
openalex +1 more source
Vascular Health and Risk Management, 2016 Tiffany Y Hu,1 Vaibhav R Vaidya,2 Samuel J Asirvatham2,31Mayo Medical School, 2Division of Cardiovascular Diseases, Department of Internal Medicine, 3Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USAAbstract: Novel oral ...
Hu TY, Vaidya VR, Asirvatham SJ
doaj
Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab [PDF]
, 2016 Jörg Berrouschot +3 more
openalex +1 more source